Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations

Click to increase image sizeClick to decrease image size

Declaration of interest

SS in a consultant and member of the speaker bureau for Gilead and AbbVie. There has been no financial support for this study. This includes royalties, grants or patents received or pending, stock ownership or options, or employments. We declare that this manuscript is original and has not been published before and has not been submitted for publication elsewhere. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewers disclosure

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Author contributions

Role in the Study: Study concept and design (SS); acquisition of data (DV, CB); analysis and interpretation of data (all); drafting of the manuscript (DV, SS); critical revision of the manuscript for important intellectual content (All); obtained funding (not applicable); administrative, technical, or material support (SS); study supervision (SS).

Additional information

Funding

This paper was not funded.